Cargando…
Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018
BACKGROUND: The first biosimilar product filgrastim-sndz was approved by the FDA in 2015, but real-world evaluations of its uptake and cost in nationally representative populations are limited. OBJECTIVE: To evaluate the uptake and cost of filgrastim-sndz, relative to its originator filgrastim and a...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391058/ https://www.ncbi.nlm.nih.gov/pubmed/33908273 http://dx.doi.org/10.18553/jmcp.2021.27.5.660 |